Abstract:Background:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with highly heterogeneous clinical presentation characterized by disease unpredictable flares and multi-systemic involvement1 2. This clinical heterogeneity calls for design a molecular stratification to improve clinical trial design and formulate personalization treatment therapies.Objectives:This research was conducted to develop a reliable method to stratify SLE patients combined gene expression information and disease status.Methods:The mRNA expression profile of GSE138458 (contained 307 patients and 23 controls) and GSE49454 (contained 111 patients and 16 controls) were downloaded from the publicly GEO databases. After background adjustment, batch correction, and other pre-procession, obtaining a big gene matrix to identify the differentially expressed genes (DEGs) in SLE compared with healthy controls, which were screened by P value < 0.01. SLE subtypes were identified by non-negative matrix factorization (NMF) based on DEGs. Acquired signature genes in different SLE subtypes were conducted to process pathway enrichment analysis in Metascape. SLEDAI score and immune cell infiltration was also performed between subtypes by software package R (version 4.0.3).Results:Total 1202 DEGs were imputed to NMF unsupervised machine learning method. Patients with SLE were stratified into two subsets based on 184 signature genes derived from obtained DEGs(Fig.1A, 1B). GO and KEGG enrichment analysis showed that signature genes were mainly involved in negative regulation of innate immune response, toll-like receptor signaling pathway, regulation of immune effector process and so on(Fig.1C). Patients in Sub1 group had severe disease activity measures compared with those in Sub2(Fig.1D). SLEDAI scores from GSE49454 dataset were also higher in Sub1 compare with Sub2(Fig.1E). Further, immune cell infiltration results revealed an insufficient of regulatory T cell, CD8 T cells and naive CD4 T cells in Sub1 and neutrophils cells in Sub2(P<0.05)(Fig.1F).Conclusion:Our findings indicate that patients with SLE could be stratified into 2 subtypes which had different lymphocyte status and closely related to disease activity. This phenotyping may help us understand the etiology of the disease, inform patient in the design of clinical trials and guide treatment decision.References:[1]Dorner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393(10188):2344-58. doi: 10.1016/S0140-6736(19)30546-X [published Online First: 2019/06/11].[2]Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Annals of the rheumatic diseases 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272 [published Online First: 2020/10/15].Acknowledgements:This project was supported by National Science Foundation of China (82001740), Open Fund from the Key Laboratory of Cellular Physiology (Shanxi Medical University) (KLCP2019) and Innovation Plan for Postgraduate Education in Shanxi Province (2020BY078).Disclosure of Interests:None declared

A Proteomic Study of Peripheral Blood Mononuclear Cells in Systemic Lupus Erythematosus.

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

Novel Long Non-coding RNA Expression Profile of Peripheral Blood Mononuclear Cells Reveals Potential Biomarkers and Regulatory Mechanisms in Systemic Lupus Erythematosus

Serum Proteomics Study Reveals Candidate Biomarkers for Systemic Lupus Erythematosus.

Comparative proteomics analysis of plasma protein in patients with neuropsychiatric systemic lupus erythematosus

Combined proteomics and single cell RNA-sequencing analysis to identify biomarkers of disease diagnosis and disease exacerbation for systemic lupus erythematosus

Analysis of Gene Expression Profiles in Human Systemic Lupus Erythematosus Using Oligonucleotide Microarray

Gene expression profile of peripheral blood B cells from patients with systemic lupus erythematosus using oligonucleotide DNA microarray

Potential Therapeutic Target Genes for Systemic Lupus Erythematosus: a Bioinformatics Analysis.

Serum Proteome and Metabolome Uncover Novel Biomarkers for the Assessment of Disease Activity and Diagnosing of Systemic Lupus Erythematosus

The Chromatin Accessibility Landscape of Peripheral Blood Mononuclear Cells in Patients with Systemic Lupus Erythematosus at Single-Cell Resolution.

Single-cell analysis with childhood and adult systemic lupus erythematosus

Different Roles of Urinary Light Chains and Serum Light Chains As Potential Biomarkers for Monitoring Disease Activity in Systemic Lupus Erythematosus.

B cell subsets-related biomarkers and molecular pathways for systemic lupus erythematosus by transcriptomics analyses

iTRAQ-based mass spectrometry screen to identify serum biomarkers in systemic lupus erythematosus

Downregulated Expression of LBH Mrna in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus

Gene Expression Profiles of Peripheral Blood in a Family with Systemic Lupus Erythematosus

POS0736 IDENTIFICATION OF MOLECULAR PHENOTYPES AND IMMUNE CELL INFILTRATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ACCORDING TO LONGITUDINAL GENE EXPRESSION

The study of the relationship between the changes of peripheral blood mononuclear cells expression of FcγR Ⅱb, serum sCD30 and the drift of Th1/Th2 cells in systemic lupus erythematosus patients

Multidimensional Single Cell Based STAT Phosphorylation Profiling Identifies a Novel Biosignature for Evaluation of Systemic Lupus Erythematosus Activity.